SILO PHARMA, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
SILO PHARMA, INC. (SILO) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $8.52 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2023-08-11
- SILO PHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2023-06-30 was $8.52K.
- SILO PHARMA, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2023-03-31 was $5.24K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month |
|---|---|---|
| 2023-06-30 | $8.52K 10-Q · filed 2023-08-11 | $3.28K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $5.24K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |